Your Health, We Care
Release date: 2026-04-27 15:39:00 Recommended: 4
Many eczema patients have long relied on topical steroids or other therapies, but the results may be unsatisfactory, or they may not be able to persist due to concerns about side effects. A study involving over a thousand people revealed a concerning reality: about 60% of patients with moderate-to-severe eczema are not satisfied with their disease control. This means that a large number of people are still suffering from unnecessary itching and skin lesions. If this applies to you, it is time to have a more meaningful conversation with your doctor. You can proactively describe symptom frequency, itch intensity, the effectiveness and shortcomings of your current treatment regimen, and clearly express your treatment goals – such as achieving nearly complete skin clearance, rapid itch relief, and reducing the frequency of flare-ups. Abrocitinib, as a once-daily oral option, has been proven in clinical trials to provide significant improvement for many patients.
Eczema (atopic dermatitis) is a skin condition affecting millions of people, with symptoms and appearance varying from person to person, and severity ranging from mild to severe. Typical manifestations include: intense itching, skin inflammation (appearing red on light skin tones, and possibly dark brown, purple, or ashen-gray patches on darker skin tones), small bumps that may ooze fluid, thickened skin, and scaling. In the United States, approximately 8.7 million people aged 12 and older have moderate-to-severe eczema, and about 60% of them have inadequately controlled disease. Eczema not only affects appearance but also imposes a heavy burden on daily life, sleep, work, and mental health due to its persistent itching and recurring nature. Recognizing this is the first step toward seeking more effective treatment.
The causes of eczema are complex, involving genetic factors and environmental triggers, but abnormal immune system reactions play a key role. The process is as follows: First, an irregular immune response occurs within the skin; this abnormal immune response then triggers inflammation in the skin tissue; finally, the inflammation manifests on the skin surface as various visible signs of eczema – redness, rash, scaling, etc. Therefore, effective treatment should not only focus on relieving surface symptoms but also aim to regulate the immune system and suppress inflammation. Abrocitinib, a JAK inhibitor, works by interfering with immune signaling pathways, thereby fundamentally reducing the symptoms of eczema.
